Munich Startup
Mermaid Bio

Mermaid Bio

Today’s antibody drugs reach only 10% of their potential targets, leaving many patients without treatment options. Mermaid Bio is pioneering the development of intrabody therapies to give patients new hope. Using cutting-edg...

Founded2026
Business ModelB2B
IndustryBioTech
This content was machine translated.

About Mermaid Bio

Today’s antibody drugs reach only 10% of their potential targets, leaving many patients without treatment options. Mermaid Bio is pioneering the development of intrabody therapies to give patients new hope. Using cutting-edge biotechnology, the company develops antibodies for intracellular targets (intrabodies) and treats diseases from within. Mermaid Bio is developing the next generation of antibody drugs to treat currently untreated patients in the future.

More like this

Discover relevant articles, startups, and events from the ecosystem

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

B2BBioTech

2026Founded
-Team size
Seed stage

ProviGenAI

ProviGenAI develops a software platform for automated experiments and data-driven process optimization. Many laboratories and biotechnology development environments already have extensive automation in place, yet the planning, evaluation, and adaptation of experiments continues to be done manually. Our platform combines automated laboratory workflows with AI-based optimization. It translates experimental protocols into executable workflows, orchestrates experiments on existing automation systems, and analyzes the resulting data to continuously improve parameters. This creates closed learning loops between experiment, analysis, and decision-making. Teams can optimize biotechnological processes—such as fermentation, screening, or bioprocess development—significantly faster and more efficiently.

B2BBioTech

2026Founded
-Team size
Seed stage